Canaccord Genuity Maintains Buy on Quipt Home Medical, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Richard Close maintains a Buy rating on Quipt Home Medical (NASDAQ:QIPT) but lowers the price target from $9 to $8.
May 17, 2024 | 2:43 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on Quipt Home Medical but lowers the price target from $9 to $8.
The maintained Buy rating suggests continued confidence in the company's performance, but the lowered price target indicates a more cautious outlook on its short-term valuation.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100